NASDAQ:KPRX Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis $0.72 -0.10 (-12.28%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$0.73 +0.01 (+0.81%) As of 11/20/2026 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Kiora Pharmaceuticals Stock (NASDAQ:KPRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kiora Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.72▼$0.8250-Day Range$0.72▼$2.7652-Week Range$0.72▼$2.91Volume64,689 shsAverage Volume80,057 shsMarket Capitalization$3.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for retinal and other eye diseases. Its research centers on therapies intended to address conditions with limited treatment options. The company’s pipeline includes KIO-301, an investigational photoswitch designed to restore light sensitivity in people with retinitis pigmentosa and other inherited retinal degenerative diseases. Kiora is also developing KIO-101, an investigational therapy for inflammatory eye diseases, including non-infectious uveitis. Formerly known as EyeGate Pharmaceuticals, the company adopted the Kiora Pharmaceuticals name in 2021. Its development programs are investigational and have not been established as effective treatments.AI Generated. May Contain Errors. Read More Kiora Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreKPRX MarketRank™: 0.33108866442 of 5 starsKiora Pharmaceuticals scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingKiora Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageKiora Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Kiora Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiora Pharmaceuticals is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiora Pharmaceuticals is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKiora Pharmaceuticals has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.29% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.84, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently increased by 1,248.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKiora Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiora Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows3 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.52% of the stock of Kiora Pharmaceuticals is held by insiders.Percentage Held by Institutions76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiora Pharmaceuticals' insider trading history. Receive KPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KPRX Stock News HeadlinesKiora Pharmaceuticals Faces High-Stakes Risk in KIO-401 Deal with Senju as 2040 Regulatory Deadline LoomsNovember 13, 2026 | tipranks.comKiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 12, 2026 | finance.yahoo.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 22 at 1:00 AM | Weiss Ratings (Ad)Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), Stryker (SYK)November 1, 2026 | theglobeandmail.comKiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset ...October 29, 2026 | finance.yahoo.comKiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory AffairsSeptember 8, 2026 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Joint (JYNT) and Kiora Pharmaceuticals (KPRX)August 9, 2026 | theglobeandmail.comKiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive PlanJune 11, 2026 | tipranks.comSee More Headlines KPRX Stock Analysis - Frequently Asked Questions How have KPRX shares performed this year? Kiora Pharmaceuticals' stock was trading at $1.97 at the start of the year. Since then, KPRX stock has decreased by 63.4% and is now trading at $0.7202. How were Kiora Pharmaceuticals' earnings last quarter? Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) posted its quarterly earnings data on Thursday, November, 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.10. The firm earned $1 million during the quarter, compared to analyst estimates of $1 million. When did Kiora Pharmaceuticals' stock split? Kiora Pharmaceuticals shares reverse split on the morning of Tuesday, June 11th 2024.The 1-9 reverse split was announced on Tuesday, June 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. When did Kiora Pharmaceuticals IPO? Kiora Pharmaceuticals (KPRX) raised $4 million in an initial public offering (IPO) on Wednesday, July 29th 2015. The company issued 683,250 shares at $6.00 per share. How do I buy shares of Kiora Pharmaceuticals? Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kiora Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiora Pharmaceuticals investors own include Esports Entertainment Group (GMBL), Intel (INTC), onsemi (ON), Tesla (TSLA), Alibaba Group (BABA), ChargePoint (CHPT) and American Battery Technology (ABML). Company Calendar Last Earnings11/12/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, KPRX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:KPRX CIK1372514 Webwww.kiorapharma.com Phone(858) 224-9600FaxN/AEmployees13Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.84 million Net MarginsN/A Pretax Margin-1,324.80% Return on Equity-82.06% Return on Assets-55.72% Debt Debt-to-Equity RatioN/A Current Ratio7.91 Quick Ratio7.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.46 per share Price / Book0.21Miscellaneous Outstanding Shares4,424,000Free Float4,401,000Market Cap$3.19 million OptionableNot Optionable Beta-0.13 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:KPRX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.